每周股票复盘：千金药业（600479）收购两子公司股权

Core Viewpoint - Qianjin Pharmaceutical (600479) is set to enhance its profitability and optimize resource allocation through the acquisition of stakes in Qianjin Xiangjiang Pharmaceutical and Qianjin Xieli Pharmaceutical, aiming to implement its "one main, two auxiliary" strategic plan [1][2]. Group 1: Company Performance - As of September 26, 2025, Qianjin Pharmaceutical's stock closed at 10.37 yuan, down 1.52% from the previous week [1]. - The company's total market capitalization is 4.34 billion yuan, ranking 46th out of 67 in the traditional Chinese medicine sector and 3610th out of 5157 in the A-share market [1]. Group 2: Transaction Details - Qianjin Pharmaceutical plans to issue shares and pay cash to acquire 28.92% of Qianjin Xiangjiang Pharmaceutical and 68.00% of Qianjin Xieli Pharmaceutical, with a total transaction value of 623.47 million yuan [1][3]. - The transaction will increase Qianjin Pharmaceutical's stake in Qianjin Xiangjiang Pharmaceutical to 79.92% and achieve 100% ownership of Qianjin Xieli Pharmaceutical [1][3]. Group 3: Regulatory Approval - The transaction has received registration approval from the China Securities Regulatory Commission (CSRC) and has passed the necessary decision-making procedures [2]. - An independent financial advisor report from Guotou Securities confirms that the transaction complies with regulations and fair pricing, with performance commitment agreements signed by the parties involved [2].